RVMD Revolution Medicines, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1628171 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-94.6%
TTM EPS YoY-75.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-93.6%
ROA-57.1%
ROIC (approx.)-84.1%
Asset turnover—
Leverage & solvency
Liabilities / assets44.2%
Debt / equity0.00x
Current ratio8.36x
Interest coverage-20.62x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $987.33M | $592.23M |
| SG&A expense | $195.04M | $97.30M |
| Operating income | -$1.18B | -$689.52M |
| Interest expense | $24.23M | $0 |
| Pretax income | -$1.13B | -$600.85M |
| Income tax | $0 | -$753,000 |
| Net income | -$1.13B | -$600.09M |
| EBITDA | -$1.17B | -$682.97M |
| EPS (basic) | -5.95 | -3.58 |
| EPS (diluted) | -5.95 | -3.58 |
| Weighted avg. shares (diluted) | 190.13M | 167.74M |
| Balance sheet | ||
| Cash & equivalents | $383.75M | $543.06M |
| Short-term investments | $1.64B | $1.75B |
| Receivables | $0 | — |
| Inventory | $0 | — |
| Current assets | $2.08B | $2.33B |
| PP&E, net | $33.19M | $24.29M |
| Goodwill | $14.61M | $14.61M |
| Intangibles | $55.80M | $56.67M |
| Total assets | $2.35B | $2.56B |
| Current liabilities | $290.42M | $163.91M |
| Total liabilities | $723.21M | $293.10M |
| Shareholders' equity | $1.63B | $2.27B |
| Shares outstanding | 197.00M | 185.90M |
| Cash flow statement | ||
| Operating cash flow | -$897.74M | -$557.44M |
| Capital expenditure | $15.99M | $10.31M |
| Free cash flow | -$913.73M | -$567.74M |
| Investing cash flow | $118.06M | -$554.39M |
| Financing cash flow | $621.52M | $959.41M |
| Depreciation & amortization | $7.78M | $6.56M |
| Stock-based compensation | $118.39M | $79.20M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.